Calzetti S, Negrotti A, Cassio A
Istituto di Neurologia, Universita' di Parma, Italy.
Clin Neuropharmacol. 1995 Jun;18(3):250-7. doi: 10.1097/00002826-199506000-00005.
The therapeutic efficacy of L-deprenyl (10 mg daily) as an adjunct to low-dose bromocriptine monotherapy (up to 25 mg daily) in patients with early Parkinson's disease (PD) was evaluated in a double-blind placebo-controlled short-term study (11 patients) and subsequently in a long-term prospective open follow-up (21 patients) until L-dopa was required, over a 4-year period. The combined regimen of bromocriptine plus L-deprenyl produced a mildly significant improvement, as shown by the majority of clinical rating scales used after 6 weeks of sustained treatment (as compared to bromocriptine alone and bromocriptine plus placebo). In the prospective long-term study, a stabilization of the clinical status was observed until 12 months of sustained treatment, whereas after that, a gradual worsening of the scores on all motor rating scales occurred. However, at 24 months, fewer than one third of the patients had required L-dopa, a proportion comparatively smaller than that reported in the literature with bromocriptine alone. This finding could be related to the persistence of initial symptomatic effect of L-deprenyl, but a slowing action on the course of the disease process exerted by the monoamine oxidase typeB (MAO-B) inhibitor cannot be ruled out.
在一项双盲安慰剂对照短期研究（11例患者）中，随后在一项为期4年的长期前瞻性开放随访研究（21例患者）中，评估了L-司来吉兰（每日10毫克）作为低剂量溴隐亭单药治疗（每日剂量高达25毫克）辅助药物，用于早期帕金森病（PD）患者的疗效，直至需要使用左旋多巴。溴隐亭加L-司来吉兰的联合治疗方案产生了轻度显著改善，持续治疗6周后使用的大多数临床评定量表显示了这一点（与单独使用溴隐亭和溴隐亭加安慰剂相比）。在长期前瞻性研究中，观察到临床状态在持续治疗12个月前保持稳定，而在那之后，所有运动评定量表的评分逐渐恶化。然而，在24个月时，不到三分之一的患者需要使用左旋多巴，这一比例相对低于文献中单独使用溴隐亭的报道。这一发现可能与L-司来吉兰初始症状性作用的持续存在有关，但不能排除单胺氧化酶B型（MAO-B）抑制剂对疾病进程的延缓作用。
